Akebia Therapeutics, Inc. (AKBA)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 62,472 | 57,336 | 37,428 | 43,648 |
| Selling, general and administrative | 26,555 | 25,742 | 26,516 | 26,917 |
| Restructuring | - | - | - | - |
| Research and development | 11,013 | 9,754 | 8,487 | 7,647 |
| License | 896 | 701 | 769 | 762 |
| Total operating expenses | 38,464 | 36,197 | 35,772 | 35,326 |
| Amortization of intangible asset | - | - | 9,011 | 9,011 |
| Cost of product and other revenue | 9,919 | 7,625 | 5,150 | 8,036 |
| Total cost of goods sold | 9,919 | 7,625 | 14,161 | 17,047 |
| Income (loss) from operations | 14,089 | 13,514 | -12,505 | -8,725 |
| Interest expense | -6,834 | -7,770 | -6,661 | -2,149 |
| Loss on extinguishment of debt | - | - | - | - |
| Change in fair value of warrant liability | 6,980 | -155 | 856 | -2,331 |
| Other income (expense) | -28 | 213 | -17 | -39 |
| Net income (loss) before income taxes | 247 | 6,112 | -20,039 | -8,582 |
| Net income (loss) | 247 | 6,112 | - | - |
| Comprehensive income (loss) | 247 | 6,112 | -20,039 | -8,582 |
| Net loss, diluted | - | - | -20,039 | - |
| Net (loss) income, basic | - | - | - | -8,582 |
| Basic (in dollars per share) | - | 0.03 | -0.1 | -0.04 |
| Basic (in shares) | 262,565,500 | 235,497,720 | 210,348,459 | 209,705,397 |
| Diluted (in dollars per share) | - | 0.03 | -0.1 | -0.04 |
| Diluted (in shares) | 271,104,020 | 241,602,853 | 210,348,459 | 209,705,397 |